Compass CEO pledges 'go slow' psychedelic drug launch — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Compass Pathways CEO Kabir Nath pledged a cautious rollout of COMP360, saying the company will "go slow before we go fast" to avoid damaging the broader psychedelics sector with early launch missteps.
- Compass Pathways is completing a rolling FDA submission this quarter for COMP360 (synthetic psilocybin for treatment-resistant depression), with the FDA expected to require a REMS program — and the company investing in provider training, CMS/insurer engagement on reimbursement, while declining to commit to specific pricing relative to Johnson & Johnson's Spravato.
- COMP360 Phase 3 trials found roughly 25% of patients had a clinically meaningful response after a single dose, rising to about 40% after a second dose three weeks later, with benefits lasting up to a year.
- Steven Hyman (former NIMH director) flagged the "unblinding" problem — patients can tell they received the drug due to its distinctive effects — which contributed to the FDA's 2024 rejection of Lykos Therapeutics' MDMA-based therapy, and questioned whether the psychedelic experience itself is necessary for therapeutic effect.
- Compass Pathways deliberately kept psychotherapy out of its clinical trials — analysis found ~80% of treatment session time was spent in silence — arguing its job is to develop a drug, not dictate how physicians provide psychological care.
Why it matters: Nath's caution signals psychedelic therapy's commercial future hinges on the first launch going smoothly — early missteps could spook regulators and investors across the sector. With REMS likely, six-hour supervised sessions, and pricing relative to Spravato undecided, patient access depends on reimbursement from CMS and commercial insurers that Compass hasn't yet secured.
Ask SkimNews
